Harrow (NASDAQ:HROW) Shares Down 5.7% – What’s Next?

Shares of Harrow, Inc. (NASDAQ:HROW) were down 5.7% during trading on Wednesday. The company traded as low as $28.64 and last traded at $28.64. Approximately 307,873 shares traded hands during trading, a decline of 56% from the average daily volume of 696,100 shares. The stock had previously closed at $30.36.

Trending Headlines about Harrow

These are some of the HROW headlines that stood out recently:

• Positive Sentiment: Harrow reported record Q3 revenue of $99.3 million, up 39% year over year. Branded revenue rose 62% to $83.5 million, and adjusted EBITDA was $21.2 million. The company reaffirmed full-year revenue guidance of $350 million to $365 million. Harrow Q3 2026 results
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $63 price target, implying substantial upside from the cited share price. BTIG Research ratings
• Negative Sentiment: Q3 GAAP net income of $9.8 million included a $5 million litigation-settlement gain, while adjusted EBITDA fell from $22.8 million a year earlier. This suggests the headline profit improvement may overstate underlying operating progress. Harrow Q3 2026 results

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Leerink Partners began coverage on Harrow in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research report on Friday, October 16th. Wall Street Zen raised shares of Harrow from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Zacks Research cut shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 3rd. Finally, BTIG Research restated a “buy” rating and issued a $63.00 price target on shares of Harrow in a research report on Wednesday. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $66.17.

Harrow Price Performance

The stock has a market cap of $1.11 billion, a P/E ratio of -37.83 and a beta of 0.18. The business has a 50-day simple moving average of $31.30 and a 200 day simple moving average of $37.74. The company has a current ratio of 2.24, a quick ratio of 2.08 and a debt-to-equity ratio of 19.70.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.06. Harrow had a negative return on equity of 68.20% and a negative net margin of 9.39%. The company had revenue of $99.30 million during the quarter, compared to the consensus estimate of $98.59 million. On average, analysts forecast that Harrow, Inc. will post -0.02 earnings per share for the current year.

Insider Buying and Selling

In other Harrow news, insider Amir Shojaei sold 11,250 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $40.00, for a total transaction of $450,000.00. Following the completion of the sale, the insider directly owned 11,250 shares in the company, valued at approximately $450,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Harrow

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE bought a new position in shares of Harrow during the 2nd quarter worth approximately $4,565,000. FirstWave Capital Management LLC increased its stake in shares of Harrow by 47.3% in the 2nd quarter. FirstWave Capital Management LLC now owns 211,981 shares of the company’s stock valued at $9,003,000 after acquiring an additional 68,058 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Harrow by 56.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock valued at $20,428,000 after acquiring an additional 208,972 shares in the last quarter. Luxor Capital Group LP increased its stake in shares of Harrow by 22.0% in the 1st quarter. Luxor Capital Group LP now owns 1,119,400 shares of the company’s stock valued at $39,470,000 after acquiring an additional 201,859 shares in the last quarter. Finally, Rice Hall James & Associates LLC acquired a new position in shares of Harrow during the 2nd quarter valued at $16,459,000. Institutional investors own 72.76% of the company’s stock.

About Harrow

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.